Priovant8 Sep 2024 12:42
Priovant have been mentioned a few times on the Sareum website.
The JAK kinase family
The TYK/JAK cell signalling family (TYK2, JAK1, JAK2, JAK3) is important for maintaining a healthy immune system. TYK2 and JAK1 are involved in signalling pathways that are often deregulated in multiple autoimmune diseases, notably psoriasis.
Members of the JAK family are the targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases. In September 2022, the US Food and Drug Administration (FDA) approved Sotyktuโข (deucravacitinib), Bristol Myers Squibbโs first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis. This and other compounds targeting TYK2 and TYK2/JAK1 in multiple autoimmune disease types are currently in clinical trials (e.g. Priovant/Pfizer), offering strong clinical validation for these therapeutic targets. These include late- and mid-stage clinical trials of TYK2 and TYK2/JAK1 inhibitors for lupus, ulcerative colitis, Crohnโs disease, dermatomyositis and other autoimmune diseases.